AboutInVivoMAbanti-humanEGFR
The225monoclonalantibodyreactswithanepitopeontheextracellulardomainofhumanEGFRbelongstotheErbBfamilyofreceptors.EGFRsignalingisactivateduponbindingoneofitsligandsincludingepidermalgrowthfactor(EGF),transforminggrowthfactorα(TGFα),Amphiregulin,andheparinbindingEGF(HB-EGF).Uponactivation,EGFRtransitionsfromaninactivemonomericformtoanactivehomodimer.ThisinitiatesseveraldownstreamsignaltransductioncascadesincludingtheMAPK,AktandJNKpathways,leADIngtoDNAsynthesisandcellproliferation.EGFRoverexpressionorconstitutiveactivationareassociatedwithmanycancers.Forthisreason,anti-EGFRmonoclonalantibodymediatedimmunotherapiesarecurrentlybeingexploredascancertreatments.The225antibodyhasbeenreportedtoneutralizeEGFRsignaling.
InVivoMAbanti-humanEGFRSpecifications
| Isotype | MouseIgG1 |
| RecommendedIsotypeControl(s) | InVivoMAbmouseIgG1isotypecontrol,unknownspecificity(BE0083) |
| RecommendedInVivoPureDilutionBuffer | InVivoPurepH7.0DilutionBuffer(IP0070) |
| Immunogen | PurifiedEGFRfromA431cells |
| ReportedApplications |
|
| Endotoxin |
|
| Purity |
|
| Formulation |
|
| Sterility | 0.2μMfiltered |
| Production | Purifiedfromtissueculturesupernatantinananimalfreefacility |
| Purification | ProteinG |
| Storage | Theantibodysolutionshouldbestoredundilutedat4°C,andprotectedfromprolongedexposuretolight.Donotfreeze. |
| RRID | AB_2687801 |
